# Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors

> **NCT05884801** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 148 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** QLS1103

## Key facts

- **NCT ID:** NCT05884801
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-30
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05884801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05884801, "Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05884801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*